- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances | 413 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 3 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch | ||
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 163 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 148 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen | |
| 05.11.25 | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.10.25 | Lake Street Capital Markets initiates Genelux stock with Buy rating | 5 | Investing.com | ||
| 03.09.25 | GENELUX Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 07.08.25 | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 198 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 07.07.25 | Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 235 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,774 | -0,71 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,980 | +1,96 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IMMUNIC | 0,890 | +3,49 % | EQS-News: Immunic AG: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Annual Results
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
26.02.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| CURIS | 0,935 | -2,60 % | Curis, Inc.: Curis Provides Third Quarter 2025 Business Update | Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,400 | -0,71 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| ESPERION | 2,774 | -2,01 % | Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 | ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves... ► Artikel lesen | |
| CYBIN | 6,000 | -1,64 % | Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee | In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes... ► Artikel lesen | |
| KYNTRA BIO | 5,850 | 0,00 % | Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 | FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer... ► Artikel lesen | |
| KARYOPHARM | 7,800 | -2,50 % | Karyopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress | - Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 -
- Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer... ► Artikel lesen | |
| BIOLINERX | 2,190 | +5,04 % | BioLineRx Ltd. - 6-K, Report of foreign issuer | ||
| PROTALIX BIOTHERAPEUTICS | 2,480 | +0,81 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| EDESA BIOTECH | 1,830 | -1,08 % | Edesa Biotech, Inc.: Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study | Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 4,760 | +3,25 % | Can-Fite BioPharma Ltd.: Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy | Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 3,300 | +1,85 % | NSE - BriaCell Therapeutics Corp. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SAGIMET BIOSCIENCES | 5,050 | +4,34 % | Sagimet Biosciences Inc.: Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+2,76 %) liegt der Kurs bei 2,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.